Analytical Data
-
Gene name
BLK
- Application
-
Alternative Names
Tyrosine-protein kinase BLK; p55-Blk
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P51451
-
Expression Region
Leu241~Tyr494
-
Molecular Weight
33KDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BLK (B lymphoid tyrosine kinase) is a member of the Src family of tyrosine kinases, which plays a crucial role in the signaling pathways of B lymphocytes and other immune cells. Research on BLK has gained significant attention due to its involvement in various immune responses and its potential implications in autoimmune diseases and lymphoid malignancies. Studies have demonstrated that BLK phosphorylation is essential for the activation and proliferation of B cells, thereby influencing the development of effective immune responses. Moreover, alterations in BLK expression and activity have been linked to the pathogenesis of certain cancers, including B-cell chronic lymphocytic leukemia (CLL) and other hematological malignancies. Understanding the molecular mechanisms governing BLK function and its interactions with other signaling pathways is critical for uncovering its role in immune regulation and disease. Consequently, the development of BLK-targeted therapies may offer promising approaches in treating diseases characterized by dysregulated B cell activity. Overall, the ongoing research on BLK and its signaling pathways continues to illuminate its potential as a therapeutic target in immunology and oncology.
